Your browser doesn't support javascript.
loading
Long-Term Survival After Venous Thromboembolism: A Prospective Cohort Study.
Nilius, Henning; Mertins, Tamara; Boss, Robin; Knuchel, Matthias; Blozik, Eva; Kremer Hovinga, Johanna Anna; Eichinger, Sabine; Nagler, Michael.
Afiliação
  • Nilius H; University Institute of Clinical Chemistry, Inselspital University Hospital, University of Bern, Bern, Switzerland.
  • Mertins T; Department of Epidemiology, Maastricht University, Maastricht, Netherlands.
  • Boss R; University Institute of Clinical Chemistry, Inselspital University Hospital, University of Bern, Bern, Switzerland.
  • Knuchel M; University Institute of Clinical Chemistry, Inselspital University Hospital, University of Bern, Bern, Switzerland.
  • Blozik E; University Institute of Clinical Chemistry, Inselspital University Hospital, University of Bern, Bern, Switzerland.
  • Kremer Hovinga JA; Department of Health Sciences, Helsana Group, Zuerich, Switzerland.
  • Eichinger S; Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
  • Nagler M; Department of Medicine 1, Medical University of Vienna, Vienna, Austria.
Front Cardiovasc Med ; 8: 749342, 2021.
Article em En | MEDLINE | ID: mdl-34660749
ABSTRACT

Background:

Little is known about long-term survival after the initial treatment of venous thromboembolism (VTE). In a prospective cohort study, we aimed to assess the long-term mortality and key predictor variables relating to disease severity, treatment intensity, and comorbidities. Materials and

Methods:

Between 1988 and 2018, 6,243 consecutive patients with VTE from a University outpatient unit were prospectively included and followed until December 2019; clinical characteristics, measures of disease severity, and treatment details were recorded. Dates of death were retrieved from the Swiss Central Compensation Office.

Results:

Overall, 254 deaths occurred over an observation period of 57,212 patient-years. Compared to the Swiss population, the standardized mortality ratio was 1.30 (95% CI 1.14, 1.47; overall mortality rate 4.44 per 1,000 patient-years). The following predictors were associated with increased mortality Unprovoked VTE (hazard ratio [HR] 5.06; 95% CI 3.29, 7.77), transient triggering risk factors (HR 3.46; 95% CI 2.18, 5.48), previous VTE (HR 2.05; 95% CI 1.60, 2.62), pulmonary embolism (HR 1.45, 95% CI 1.10, 1.89), permanent anticoagulant treatment (HR 3.14; 95% CI 2.40, 4.12), prolonged anticoagulant treatment (7-24 months; HR 1.70; 95% CI 1.16, 2.48), and cardiovascular comorbidities. Unprovoked VTE, previous VTE, permanent and prolonged anticoagulation remain independent risk factors after adjustment for age, sex, and comorbidities.

Conclusion:

Survival after VTE was significantly reduced compared to the Swiss general population, especially in patients with more severe disease, cardiovascular comorbidities, and longer anticoagulant treatment.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_venous_thromboembolic_disease Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Cardiovasc Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_venous_thromboembolic_disease Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Cardiovasc Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Suíça
...